Rome, Nov 12. (Adnkronos Health) – “We ask that genetic testing be included in the LEA, so that all patients have the same opportunity to access care, in the North as well as in the South. Knowing the genetic characteristics of the tumor and identifying the most suitable therapy is fundamental, especially for a pathology like cholangiocarcinoma, for which there is no time to lose.” So said Mirella Ferri, president of the Italian Cholangiocarcinoma Patients Association (Apic), speaking at the event ‘Essential Levels of Assistance and Next Generation Sequencing, The Challenge of Innovation between Update and Access’, organized by Salutequità in Rome.
“We hope that the drug will soon be accessible to every patient, but it is equally important to be able to perform the necessary test. As an association, we try to help our members reach specialized centers as soon as possible, because not all facilities are able to perform genetic testing. This involves travel and loss of time which, for patients, can be very burdensome,” explained Ferri.